Journal of diabetes science and technology · 2025
Continuous Glucose Monitoring and Maternal and Neonatal Morbidity in Pregnant People With Type 1 Diabetes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fisher Stephanie A, Pavan Jacopo, Villa-Tamayo María F, Fabris Chiara, Conboy Natalie E, Niznik Charlotte, Yee Lynn M, Moscoso-Vasquez Marcela, Batista Annanda Fernandes Moura B, Kohn Michael A, Kobayashi Emily, Majithia Amit R, Huang Jingtong, Tian Tiffany, Aaron Rachel E, Klonoff David
Аннотация
INTRODUCTION: Prior studies have not identified if continuous glucose monitoring (CGM) metrics at a critical gestational age window can discriminate risk of adverse pregnancy outcomes. We evaluated late second- and third-trimester CGM metrics by gestational age associated with pregnancy outcomes in gravidas with type 1 diabetes (T1DM).
METHODS: Dexcom G6 CGM data from a retrospective cohort of singleton gestations with T1DM (2018-2022) at an academic medical center were analyzed. Time in, above, and below range 63 to 140 mg/dL (TIR, TAR, TBR), glycemic variability, and mean glucose concentration were computed in two-week CGM intervals from 240 to 396 weeksdays. Adverse pregnancy outcomes were hypertensive disorders of pregnancy (HDP), large-for-gestational age (LGA), and neonatal hypoglycemia. Linear mixed-effects models were fitted on CGM metrics computed from two-week CGM intervals, with gestational age, adverse pregnancy outcomes (i.e. presence/absence of HDP, LGA, and/or neonatal hypoglycemia), and their interaction as fixed effects.
RESULTS: In 87 gravidas with preconception median hemoglobin A1c 6.5% (IQR 6.0, 7.1) and maternal body mass index 24.8 kg/m2 (IQR 21.9, 27.1), 71% had at least one adverse pregnancy outcome. Between weeks 240 and 376, gravidas with HDP had higher TAR and mean glucose and lower TIR (P < .05). Gravidas with LGA had lower TBR between weeks 240 and 356. TIR, TAR, and mean glucose evolution differed by HDP status, with greatest divergence between groups at 280 to 296 weeks' gestation (P ≤ .001).
CONCLUSION: CGM metrics in the late second to early third trimester, a period of peak insulin resistance, may help to distinguish risk of HDP and LGA in gravidas with T1DM.
METHODS: Dexcom G6 CGM data from a retrospective cohort of singleton gestations with T1DM (2018-2022) at an academic medical center were analyzed. Time in, above, and below range 63 to 140 mg/dL (TIR, TAR, TBR), glycemic variability, and mean glucose concentration were computed in two-week CGM intervals from 240 to 396 weeksdays. Adverse pregnancy outcomes were hypertensive disorders of pregnancy (HDP), large-for-gestational age (LGA), and neonatal hypoglycemia. Linear mixed-effects models were fitted on CGM metrics computed from two-week CGM intervals, with gestational age, adverse pregnancy outcomes (i.e. presence/absence of HDP, LGA, and/or neonatal hypoglycemia), and their interaction as fixed effects.
RESULTS: In 87 gravidas with preconception median hemoglobin A1c 6.5% (IQR 6.0, 7.1) and maternal body mass index 24.8 kg/m2 (IQR 21.9, 27.1), 71% had at least one adverse pregnancy outcome. Between weeks 240 and 376, gravidas with HDP had higher TAR and mean glucose and lower TIR (P < .05). Gravidas with LGA had lower TBR between weeks 240 and 356. TIR, TAR, and mean glucose evolution differed by HDP status, with greatest divergence between groups at 280 to 296 weeks' gestation (P ≤ .001).
CONCLUSION: CGM metrics in the late second to early third trimester, a period of peak insulin resistance, may help to distinguish risk of HDP and LGA in gravidas with T1DM.